Cargando…

Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury

This review summarizes current progress on development of astrocyte transplantation therapies for repair of the damaged central nervous system. Replacement of neurons in the injured or diseased central nervous system is currently one of the most popular therapeutic goals, but if neuronal replacement...

Descripción completa

Detalles Bibliográficos
Autores principales: Noble, Mark, Davies, Jeannette E., Mayer-Pröschel, Margot, Pröschel, Christoph, Davies, Stephen J. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210359/
https://www.ncbi.nlm.nih.gov/pubmed/21918888
http://dx.doi.org/10.1007/s13311-011-0071-z
_version_ 1782215728196222976
author Noble, Mark
Davies, Jeannette E.
Mayer-Pröschel, Margot
Pröschel, Christoph
Davies, Stephen J. A.
author_facet Noble, Mark
Davies, Jeannette E.
Mayer-Pröschel, Margot
Pröschel, Christoph
Davies, Stephen J. A.
author_sort Noble, Mark
collection PubMed
description This review summarizes current progress on development of astrocyte transplantation therapies for repair of the damaged central nervous system. Replacement of neurons in the injured or diseased central nervous system is currently one of the most popular therapeutic goals, but if neuronal replacement is attempted in the absence of appropriate supporting cells (astrocytes and oligodendrocytes), then the chances of restoring neurological functional are greatly reduced. Although the past 20 years have offered great progress on oligodendrocyte replacement therapies, astrocyte transplantation therapies have been both less explored and comparatively less successful. We have now developed successful astrocyte transplantation therapies by pre-differentiating glial restricted precursor (GRP) cells into a specific population of GRP cell-derived astrocytes (GDAs) by exposing the GRP cells to bone morphogenetic protein-4 (BMP) prior to transplantation. When transplanted into transected rat spinal cord, rat and human GDAs(BMP) promote extensive axonal regeneration, rescue neuronal cell survival, realign tissue structure, and restore behavior to pre-injury levels on a grid-walk analysis of volitional foot placement. Such benefits are not provided by GRP cells themselves, demonstrating that the lesion environment does not direct differentiation in a manner optimally beneficial for the restoration of function. Such benefits also are not provided by transplantation of a different population of astrocytes generated from GRP cells exposed to ciliary neurotrophic factor (GDAs(CNTF)), thus providing the first transplantation-based evidence of functional heterogeneity in astrocyte populations. Moreover, lessons learned from the study of rat cells are strongly predictive of outcomes using human cells. Thus, these studies provide successful strategies for the use of astrocyte transplantation therapies for restoration of function following spinal cord injury. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13311-011-0071-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3210359
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-32103592011-11-28 Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury Noble, Mark Davies, Jeannette E. Mayer-Pröschel, Margot Pröschel, Christoph Davies, Stephen J. A. Neurotherapeutics Review This review summarizes current progress on development of astrocyte transplantation therapies for repair of the damaged central nervous system. Replacement of neurons in the injured or diseased central nervous system is currently one of the most popular therapeutic goals, but if neuronal replacement is attempted in the absence of appropriate supporting cells (astrocytes and oligodendrocytes), then the chances of restoring neurological functional are greatly reduced. Although the past 20 years have offered great progress on oligodendrocyte replacement therapies, astrocyte transplantation therapies have been both less explored and comparatively less successful. We have now developed successful astrocyte transplantation therapies by pre-differentiating glial restricted precursor (GRP) cells into a specific population of GRP cell-derived astrocytes (GDAs) by exposing the GRP cells to bone morphogenetic protein-4 (BMP) prior to transplantation. When transplanted into transected rat spinal cord, rat and human GDAs(BMP) promote extensive axonal regeneration, rescue neuronal cell survival, realign tissue structure, and restore behavior to pre-injury levels on a grid-walk analysis of volitional foot placement. Such benefits are not provided by GRP cells themselves, demonstrating that the lesion environment does not direct differentiation in a manner optimally beneficial for the restoration of function. Such benefits also are not provided by transplantation of a different population of astrocytes generated from GRP cells exposed to ciliary neurotrophic factor (GDAs(CNTF)), thus providing the first transplantation-based evidence of functional heterogeneity in astrocyte populations. Moreover, lessons learned from the study of rat cells are strongly predictive of outcomes using human cells. Thus, these studies provide successful strategies for the use of astrocyte transplantation therapies for restoration of function following spinal cord injury. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13311-011-0071-z) contains supplementary material, which is available to authorized users. Springer-Verlag 2011-09-15 2011-10 /pmc/articles/PMC3210359/ /pubmed/21918888 http://dx.doi.org/10.1007/s13311-011-0071-z Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Noble, Mark
Davies, Jeannette E.
Mayer-Pröschel, Margot
Pröschel, Christoph
Davies, Stephen J. A.
Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title_full Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title_fullStr Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title_full_unstemmed Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title_short Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury
title_sort precursor cell biology and the development of astrocyte transplantation therapies: lessons from spinal cord injury
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210359/
https://www.ncbi.nlm.nih.gov/pubmed/21918888
http://dx.doi.org/10.1007/s13311-011-0071-z
work_keys_str_mv AT noblemark precursorcellbiologyandthedevelopmentofastrocytetransplantationtherapieslessonsfromspinalcordinjury
AT daviesjeannettee precursorcellbiologyandthedevelopmentofastrocytetransplantationtherapieslessonsfromspinalcordinjury
AT mayerproschelmargot precursorcellbiologyandthedevelopmentofastrocytetransplantationtherapieslessonsfromspinalcordinjury
AT proschelchristoph precursorcellbiologyandthedevelopmentofastrocytetransplantationtherapieslessonsfromspinalcordinjury
AT daviesstephenja precursorcellbiologyandthedevelopmentofastrocytetransplantationtherapieslessonsfromspinalcordinjury